| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| Company: GOG Partners |
| Recipient: You |
| Company: NRG Ovarian Committee Chair |
| Recipient: Your Institution |
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| Company: Research To Practice |
| Recipient: You |
| Company: Prime Oncology |
| Recipient: You |
| Company: Physician Education Resource |
| Recipient: You |
| Company: Great Debates and Updates |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: Genentech/Roche |
| Recipient: You |
| Company: Immunogen |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: VBL Therapeutics |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Eisai |
| Recipient: You |
| Company: Onconova Therapeutics |
| Recipient: You |
| Company: Verastem/Pharmacyclics |
| Recipient: You |
| Company: AADi |
| Recipient: You |
| Company: Caris Life Sciences |
| Recipient: You |
| Company: Iovance Biotherapeutics |
| Recipient: You |
| Company: Janssen Oncology |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: zentalis |
| Recipient: You |
| Company: Mersana |
| Recipient: Your Institution |
| Company: Blueprint pharmacetuicals |
| Recipient: Your Institution |
| Company: GSK/Tesaro |
| Recipient: Your Institution |
| Company: Duality Biologics |
| Recipient: Your Institution |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: PTC Therapeutics |
| Recipient: Your Institution |
| Company: Lilly |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Tesaro |
| Recipient: Your Institution |
| Company: Genentech |
| Recipient: Your Institution |
| Company: Clovis Oncology |
| Recipient: Your Institution |
| Company: Lilly Foundation |
| Recipient: Your Institution |
| Company: Regeneron |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Verastem |
| Recipient: Your Institution |
| Company: Novartis Pharmaceuticals UK Ltd. |
| Recipient: Your Institution |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Agenus |
| Recipient: Your Institution |
| Company: Takeda |
| Recipient: Your Institution |
| Company: Immunogen |
| Recipient: Your Institution |
| Company: Novogen |
| Recipient: Your Institution |
| Company: artios |
| Recipient: Your Institution |
| Company: Bolt Biotherapeutics |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
| Company: Daiichi Sankyo/Lilly |
| Recipient: Your Institution |
| Company: cyteir |
| Recipient: Your Institution |
| Company: Immunocore |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Up to Date |
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: BioNTech SE |
| Recipient: You |
|
| Other Relationship |
| Company: GOG Partners |
| Recipient: Your Institution |
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|